首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America >Regulatable atrial natriuretic peptide gene therapy for hypertension
【24h】

Regulatable atrial natriuretic peptide gene therapy for hypertension

机译:调节性心钠素基因治疗高血压

获取原文
获取原文并翻译 | 示例
           

摘要

Hypertension (HTN) is a disease that begins with dysfunctional renal-sodium excretion and progresses to a syndrome of highly elevated systolic, diastolic, and mean arterial pressures. Inadequacies in the therapy of HTN have led to the investigation of the gene therapy of this disease by using systemic overproduction of vaso-dilatory peptides, such as atrial natriuretic peptide (ANP). However, gene-therapy approaches to HTN using ANP are limited by the need for long-term ANP gene expression and, most important, control of ANP gene expression. Here, we introduce a helper-dependent adenoviral vector carrying the mifepristone (Mfp)-inducible gene-regulatory system to control in vivo ANP expression. In the BPH/2 mouse model of HTN, Mfp-inducible ANP expression was seen for a period of > 120 days after administration of vector. Physiological effects of ANP, including decreased systolic blood pressure, increased urinary cGMP output, and decreases in heart weight as a percentage of body weight were also under the control of Mfp. Given these capabilities, this vector represents a paradigm for the gene therapy of HTN.
机译:高血压(HTN)是一种以肾钠排泄失调开始并发展为收缩压,舒张压和平均动脉压高度升高的综合征的疾病。 HTN治疗的不足之处导致了对这种疾病的基因治疗的研究,方法是使用全身过度产生的血管舒张肽,例如心钠素。但是,使用ANP进行HTN的基因治疗方法受到长期ANP基因表达以及最重要的是ANP基因表达控制的限制。在这里,我们介绍了一个带有米非司酮(Mfp)诱导型基因调控系统的辅助依赖型腺病毒载体,以控制体内ANP的表达。在HTN的BPH / 2小鼠模型中,在施用载体后观察到Mfp诱导的ANP表达> 120天。 ANP的生理效应,包括收缩压降低,尿cGMP输出增加以及心脏重量占体重的百分比降低,也受Mfp控制。有了这些功能,该载体代表了HTN基因治疗的范例。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号